Jamjoom Pharmaceuticals Factory Company

4015.SRPre-clinical

Jamjoom Pharmaceuticals is a key player in the Saudi pharmaceutical market, specializing in the production of high-quality generic medicines and consumer health products. The company has established a strong manufacturing footprint and distribution network, contributing to the Kingdom's healthcare self-sufficiency goals under Vision 2030. Its strategic focus includes expanding its product portfolio through local development and strategic partnerships, while leveraging its market position for regional growth.

Market Cap

$9.7B

Employees

500-1000

Focus

Biotech

4015.SR · Stock Price

USD 139.20+61.20 (+78.46%)

Historical price data

AI Company Overview

Technology Platform

Pharmaceutical manufacturing and formulation technology for solid, liquid, and semi-solid dosage forms, focused on developing bioequivalent generic drugs and consumer health products.

Funding History

IPOUndisclosedUndisclosedJun 15, 2022

Opportunities

Significant growth is driven by Saudi Arabia's 'Vision 2030' mandate to localize pharmaceutical production, reducing import dependency.

Expansion opportunities exist in exporting to neighboring GCC and MENA markets and in adding more complex generic products or biosimilars to the portfolio.

Risk Factors

Key risks include high dependence on the Saudi market and government tenders, exposure to regulatory pricing pressures, intense competition from both local and multinational firms, and reliance on imported raw materials subject to supply chain and cost volatility.

Competitive Landscape

Jamjoom competes with other major local Saudi manufacturers like SPIMACO and Tabuk Pharmaceuticals, as well as the Saudi subsidiaries of global pharma giants. Its competitive edge is rooted in its local manufacturing base, which is favored in government procurement, and its established brand trust and distribution network within the Kingdom.